Firms that want to correct misinformation about their Rx drugs posted on third-party social media sites should correct all misinformation within a defined area of the forum, including exaggerated efficacy claims, FDA advises in a draft guidance.
“For example, if a firm chooses to correct only misinformation that portrays its product in a negative light in a third-party communication but does not address information that overstates the benefits of its product in that same clearly defined portion of the communication,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?